Latest Life Sciences News

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

ALS Limited (ASX:ALQ) has delivered a landmark FY26 with underlying net profit after tax surging 25.8% to $381.2 million, beating 2027 targets a year early and raising its dividend by 10%. The company continues to invest heavily in automation, digital initiatives, and laboratory expansions while advancing its climate strategy amid a post-year-end cyber incident.

Lendlease is selling its 25.1% stake in the Keyton Retirement Living Trust to Aware Super for $525 million, part of a broader $3.4 billion capital recycling push aimed at debt reduction.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.

Microba Life Sciences has voluntarily suspended trading of its shares from 5 June 2026, ahead of a material capital raise and an update on its path to break even, expected by 11 June.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.